Benign neoplasms

Disease1 paper1 finding

Associations

1

Semaglutide

upin humans1OR 1.28High certainty

1 study

Semaglutide raises the risk of benign neoplasms in humans (OR 1.28, 95% CI 1.02–1.61).
Reviewtype 2 diabetes26 to 156 weeks
Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials · Frontiers in pharmacology · 3 Sep 2026

Semaglutide →

Latest

2

Frontiers in PharmacologyReview18 Sep

Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Genetics in Medicine OpenHumans27 Aug

Germline POT1 variants are associated with long telomeres and an unexpected broad spectrum of malignancies